MS drug withdrawn following brain disorders

recall regulatory
Biogen Australia is withdrawing Zinbryta (daclizumab) from the global and Australian market following cases of serious inflammatory brain disorders The TGA says it has not received any reports of inflammatory brain disorders occurring in Australian patients who have been prescribed Zinbryta. The cases of immune-mediated encephalitis and meningoencephalitis reported occurred in Europe. Biogen says it

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous My Health Record: the guidelines
Next It's time to 'get real'